What’s the current market cap for UCB stock?

UCB (UCB) has a market cap of €47bn as of June 19, 2026.

What is the P/E ratio for UCB stock?

The price to earnings (P/E) ratio for UCB (UCB) stock is 31.15 as of June 19, 2026.

Does UCB stock pay dividends?

Yes, the UCB (UCB) stock pays dividends to shareholders. As of June 19, 2026, the dividend rate is €1.015 and the yield is 0.41%. UCB has a payout ratio of 16.94% on a trailing twelve-month basis.

When is the next UCB dividend payment date?

The next UCB (UCB) dividend payment date is unconfirmed.

What is the beta indicator for UCB?

UCB (UCB) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy UCB stock | €UCB Share Price

05:30

09:10

12:45

16:25

20:00

About UCB

UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.

Ticker

€UCB

Sector

Health

Primary listing

BSE

Employees

9,765

Headquarters

Brussels, Belgium

Website

www.ucb.com

UCB Metrics

BasicAdvanced

€47bn

31.15

€8.03

0.17

€1.02

0.41%

What the Analysts think about UCB

Analyst ratings (Buy, Hold, Sell) for UCB stock.

Bulls say / Bears say

UCB’s planned acquisition of Neurona Therapeutics for up to $1.15 billion expands its gene therapy pipeline targeting drug-resistant epilepsy, potentially unlocking significant long-term growth. (Reuters)

UCB’s $2 billion investment in a biologics manufacturing plant in suburban Atlanta underscores its commitment to scaling U.S. operations, enhancing supply resilience, and supporting anticipated pipeline demand. (AP News)

UCB delivered a 79% increase in adjusted EBITDA to €2.64 billion in 2025, reflecting strong cash flow generation and operational leverage. (Reuters)

Briviact’s patent protection ends in the United States in February 2026 and in Europe in August 2026, exposing annual sales of €758 million to imminent generic competition. (Reuters)

Barclays downgraded UCB to “equal weight” citing rising R&D and acquisition costs from recent deals and a lack of meaningful clinical catalysts before 2028, weighing on its near-term earnings outlook. (Reuters)

When stripping out one-off asset sale proceeds and a contract manufacturing windfall, UCB’s underlying adjusted EBITDA margin for 2025 was 31.4%, below the 34% headline rate, indicating margin pressure. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 19 Jun 2026.

UCB Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

UCB Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Bulls say / Bears say

UCB delivered a 79% increase in adjusted EBITDA to €2.64 billion in 2025, reflecting strong cash flow generation and operational leverage. (Reuters)

Briviact’s patent protection ends in the United States in February 2026 and in Europe in August 2026, exposing annual sales of €758 million to imminent generic competition. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 19 Jun 2026.

About UCB

Ticker

Primary listing

Employees

UCB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about UCB

Analyst Ratings

Bulls say / Bears say

UCB Financial Performance

Income Statement

UCB Earnings Performance

Earnings per share (EPS)

Buy €UCB

Lightyear

Legal

Work with us

Bulls say / Bears say

UCB/€UCB

About UCB

Ticker

Primary listing

Employees

UCB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about UCB

Analyst Ratings

Bulls say / Bears say

UCB Financial Performance

Income Statement

UCB Earnings Performance

Earnings per share (EPS)

What’s the current market cap for UCB stock?

What is the P/E ratio for UCB stock?

Does UCB stock pay dividends?

When is the next UCB dividend payment date?

What is the beta indicator for UCB?

Bulls say / Bears say